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Stroke Outcomes With Vorapaxar Versus Placebo in Patients With
Acute Coronary Syndromes: Insights From the TRACER Trial
Leo Ungar, MD; Robert M. Clare, MS; Fatima Rodriguez, MD, MPH; Bradley J. Kolls, MD; Paul W. Armstrong, MD; Philip Aylward, MD;
Claes Held, MD, PhD; David J. Moliterno, MD; John Strony, MD; Frans Van de Werf, MD; Lars Wallentin, MD, PhD; Harvey D. White, DSc;
Pierluigi Tricoci, MD, PhD, MHS; Robert A. Harrington, MD; Kenneth W. Mahaffey, MD; Chiara Melloni, MD, MHS
Background-—Vorapaxar, a protease-activated receptor-1 antagonist, is approved for secondary prevention of cardiovascular
events but is associated with increased intracranial hemorrhage.
Methods and Results-—TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) was a
trial of vorapaxar versus placebo among patients with acute coronary syndrome. Strokes were adjudicated by a central events
committee. Of 12 944 patients, 199 (1.5%) had ≥1 stroke during the study period (median follow-up, 477 days). Four patients had
a single stroke of unknown type; 195 patients had ≥1 stroke classified as hemorrhagic or nonhemorrhagic (165 nonhemorrhagic,
28 hemorrhagic, and 2 both). Strokes occurred in 96 of 6473 patients (1.5%) assigned vorapaxar and 103 of 6471 patients (1.6%)
assigned placebo. Kaplan-Meier incidence of stroke for vorapaxar versus placebo was higher for hemorrhagic stroke (0.45% versus
0.14% [hazard ratio, 2.74; 95% confidence interval, 1.22–6.15]), lower but not significantly different for nonhemorrhagic stroke
(1.53% versus 1.98% at 2 years [hazard ratio, 0.79; 95% confidence interval, 0.58–1.07]), and similar for stroke overall (1.93%
versus 2.13% at 2 years [hazard ratio, 0.94; 95% confidence interval, 0.71–1.24]).
Conclusions-—Stroke occurred in <2% of patients. Vorapaxar-assigned patients had increased hemorrhagic stroke but a
nonsignificant trend toward lower nonhemorrhagic stroke. Overall stroke frequency was similar with vorapaxar versus placebo.
( J Am Heart Assoc. 2018;7:e009609. DOI: 10.1161/JAHA.118.009609.)
Key Words: acute coronary syndrome • stroke • vorapaxar
V orapaxar is a protease-activated receptor-1 antagonistapproved for secondary prevention of cardiovascular events in patients with a history of myocardial infarction (MI)or peripheral arterial disease who have not had a stroke or
transient ischemic attack (TIA).1 Although vorapaxar was
approved by the US Food and Drug Administration (FDA) in
2014,2,3 clinical use of this antiplatelet agent has been
modest.4,5
A barrier to more widespread vorapaxar use may be its
association with increased intracranial hemorrhage (ICH) in 2
phase 3 trials: TRACER (Thrombin Receptor Antagonist for
Clinical Event Reduction in Acute Coronary Syndrome) and
TRA2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary
Prevention of Atherothrombotic Ischemic Events–Thromboly-
sis in Myocardial Infarction 50).6,7 The TRACER trial, which
examined vorapaxar in acute coronary syndromes (ACSs), was
stopped after the requisite number of events per protocol had
been achieved but earlier than planned when the data safety
monitoring board observed a higher ICH rate with vorapaxar.6
The TRA2P-TIMI 50 trial, which examined vorapaxar for
secondary prevention, was allowed to continue, but patients
with previous stroke or incident stroke during the trial (in
whom bleeding risk was greater) were discontinued from the
study.7
Secondary analyses of the TRA2P-TIMI 50 trial have
further characterized vorapaxar’s hemorrhagic and overall
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stroke risk. One analysis demonstrated that vorapaxar-
assigned patients with a history of ischemic stroke had a
higher risk of bleeding and ICH but no lower risk of
ischemic events.8 Another analysis, limited to the FDA-
approved patient population, which excludes patients with a
history of stroke or TIA, demonstrated that although
vorapaxar-assigned patients had a higher rate of ICH, they
also had a lower rate of ischemic stroke and of stroke
overall.9
The aim of this analysis is to further characterize stroke
subtypes and outcomes with vorapaxar using data from the
TRACER trial.
Methods
Transparency and Openness Promotion
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
The TRACER Trial
The design of the TRACER trial has been described previously.6
In brief, the TRACER trial was a phase 3, randomized, double-
blinded, placebo-controlled, multicenter trial of vorapaxar
versus placebo in ACS. The TRACER trial was approved by
the Duke Institutional Review Board, as the coordinating
center, and by local institutional review boards. All participants
provided written informed consent. Altogether, 12 944
patients were enrolled in >800 centers in 37 countries.
Patients were randomized within 24 hours of presentation to
the hospital with ischemic symptoms, if they had either
positive cardiac biomarkers (troponin and creatine kinase-
muscle/brain [CK-MB]) or had ST-segment depression/tran-
sient elevation and an additional risk-enhancing characteristic
(aged >55 years, prior percutaneous coronary intervention,
prior coronary artery bypass graft surgery, prior MI, peripheral
arterial disease, or diabetes mellitus). Exclusion criteria
included an indication for systemic anticoagulation. Patients
with a history of atrial fibrillation were, therefore, only enrolled
if they were not receiving anticoagulation or did not have an
indication to be receiving anticoagulation. Patients were
randomized to either vorapaxar, which included a 40-mg
loading dose, followed by a 2.5-mg/d maintenance dose, or
placebo. Concomitant antiplatelet therapy was left to the
discretion of the treating physician. Most patients in the trial
were receiving dual antiplatelet therapy in addition to study
drug, with administration of aspirin to 99% and clopidogrel to
91.8% (91.7% in the placebo arm and 91.9% in the vorapaxar
arm) of patients, resulting in triple antiplatelet therapy in
most patients in the vorapaxar arm and dual antiplatelet
therapy plus placebo in most patients in the placebo arm.6
Duration of planned treatment was the entire length of the
study and a minimum of 1 year.
Patients were assessed at 30 days, 4 months, 8 months,
12 months, and every 6 months thereafter. The primary
efficacy end point was a composite that included death from
cardiovascular causes, MI, stroke, recurrent ischemia, rehos-
pitalization, or coronary revascularization. Primary safety end
points were moderate or severe bleeding, according to the
Global Use of Strategies to Open Occluded Arteries classifi-
cation, and clinically significant bleeding, according to the
TIMI classification.10,11
Stroke End Points
Suspected strokes in the TRACER trial were adjudicated and
categorized by a central events committee, which included a
vascular neurologist. Site investigators provided clinical
information on standard case report forms and clinical
information such as consult notes, procedure reports, admis-
sion and discharge notes, imaging reports, and autopsy
information, if available.
Clinical Perspective
What Is New?
• Vorapaxar is a novel antiplatelet that is approved
for secondary prevention of cardiovascular events but
has been associated with increased intracranial
hemorrhage.
• The overall stroke rate was <2% in patients with acute
coronary syndrome enrolled in the TRACER (Thrombin
Receptor Antagonist for Clinical Event Reduction in Acute
Coronary Syndrome) trial; although the overall stroke
frequency was similar between vorapaxar- and placebo-
assigned patients, those randomized to vorapaxar had more
hemorrhagic strokes.
• Patients with a history of stroke were at greater risk for any
new stroke or new ischemic stroke during follow-up, but the
risk of new hemorrhagic stroke was not significant.
What Are the Clinical Implications?
• Greater than 90% of patients enrolled in the TRACER trial
were receiving aspirin and a P2Y12 agent, such as
clopidogrel, resulting in triple antiplatelet therapy during
the course of the study; other schemes, such as
combinations of vorapaxar with either aspirin or a
P2Y12 agent, may have less bleeding risk and similar
or more benefit.
• Further research is needed to do the following: (1) identify
factors associated with hemorrhagic stroke and other
bleeding events with vorapaxar; and (2) evaluate the role
of vorapaxar as monotherapy for secondary stroke
prevention.
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Statistical Analysis
Baseline characteristics were summarized among patients
with no stroke events during the trial and among patients who
had at least one stroke, as well as by stroke type (ICH/
nonhemorrhagic) among patients experiencing an event.
Baseline characteristics were further summarized by treat-
ment group within each stroke type. Stroke attributes and
outcomes/actions after stroke were summarized by treat-
ment group. Categorical variables were presented as counts
and proportions, and continuous variables were presented as
medians with interquartile ranges. All analyses of patient and
stroke characteristics were descriptive, and no statistical
tests were performed.
The distribution of time to event for each type of stroke
(ischemic, hemorrhagic, and any), overall and within vorapaxar
and placebo groups, was assessed and 2-year rates were
estimated by the Kaplan-Meier (KM) method. Comparisons
were made by means of the log-rank test. The KM method
was also used to analyze whether there was a difference in
rates of stroke at 2 years in patients with versus without
history of stroke before trial enrollment. Baseline character-
istics were balanced between treatment arms by randomiza-
tion and, therefore, no adjustment for baseline confounders
was used in modeling outcomes on treatment. All statistical
analyses were performed using SAS software, version 9.4
(SAS Institute Inc, Cary, NC).
Results
Baseline Characteristics
Of the 12 944 patients enrolled in the TRACER trial, a total of
199 (1.5%) had ≥1 stroke (Table 1). Compared with patients
without stroke, those with strokes tended to be older (median
age, 69 years [quartile 1–quartile 3, 60–74 years] versus 64
years [quartile 1–quartile 3, 58–71 years]) and were more
likely to have a history of hypertension (80.9% versus 70.4%),
diabetes mellitus (39.2% versus 31.3%), and comorbidities
before study enrollment, such as stroke (11.1% versus 4.2%),
TIA (8.5% versus 2.4%), MI (31.7% versus 29.3%), peripheral
arterial disease (12.6% versus 7.2%), and atrial fibrillation
(10.1% versus 4.3%).
Stroke Frequency and Type
Any stroke
Of the 199 patients who experienced stroke during the study
(Table 2), 4 had a single stroke of unknown type and 195 had
at least one stroke that was classified as hemorrhagic or
nonhemorrhagic. Of the patients with at least one stroke with
a classified type, 165 experienced only nonhemorrhagic
stroke, 28 experienced only hemorrhagic stroke, and 2
experienced both a hemorrhagic and a nonhemorrhagic
stroke. Hemorrhagic conversion was seen in 3 (3.1%) of the
96 primary nonhemorrhagic strokes in the vorapaxar arm and
in 5 (4.9%) of the 103 primary nonhemorrhagic strokes in the
placebo arm (Table 2).
At least one stroke during the study period occurred in 96
(1.5%) of 6473 patients assigned vorapaxar and in 103 (1.6%)
of 6471 patients assigned placebo (Table 2). KM rates at
2 years for overall stroke in vorapaxar- versus placebo-
assigned patients were similar: 1.93% versus 2.13% (hazard
ratio [HR], 0.94; 95% confidence interval [CI], 0.71–1.24)
(Figure [A]).
Hemorrhagic stroke
Among patients having strokes during the study period,
there were proportionally more hemorrhagic strokes among
vorapaxar-assigned patients: 22 (22.9%) of 96 patients
versus 8 (7.8%) of 103 patients (Table 2). Likewise, the KM
percentage rate to 2 years for hemorrhagic stroke was
significantly higher in vorapaxar- versus placebo-assigned
patients: 0.45% versus 0.13% (HR, 2.74; 95% CI, 1.22–6.15)
(Figure [B]).
Nonhemorrhagic stroke
Among patients having strokes during the study period, there
were proportionally fewer nonhemorrhagic strokes among
vorapaxar-assigned patients: 74 (77.1%) of 96 patients versus
93 (90.3%) of 103 patients (Table 2). KM percentage rates to
2 years for nonhemorrhagic stroke were lower, but not
significantly different, in vorapaxar- versus placebo-assigned
patients: 1.53% versus 1.98% (HR, 0.79; 95% CI, 0.58–1.07)
(Figure [C]).
Baseline Characteristics of Patients by Type of
Stroke (Hemorrhagic Versus Nonhemorrhagic)
We examined baseline characteristics of patients whose first
stroke was hemorrhagic versus nonhemorrhagic, both overall
(Table 3) and by treatment assignment (Table 4). Compared
with patients whose first stroke was nonhemorrhagic stroke,
those with an initial hemorrhagic stroke were more likely to
be women (39.3% versus 25.1%) and less likely to have
hypertension (67.9% versus 82.6%) and a history of prior
stroke (3.6% versus 12.6%).
We also examined and found an association between
increased blood pressure at presentation and risk of stroke,
with an HR (95% CI) per 10–mm Hg increase in systolic
blood pressure calculated at 1.07 (1.00–1.52, P=0.051) for
ischemic stroke, 1.23 (1.05–1.43, P=0.009) for hemor-
rhagic stroke, and 1.10 (1.03–1.17, P=0.030) for any
stroke.
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Stroke Frequency in Patients With a History of
Stroke
Table 5 displays KM rates of stroke (hemorrhagic, non-
hemorrhagic, and any) at 2 years for patients with and
without stroke history. The KM rates in patients with
stroke history were significantly higher for ischemic stroke
(5.95 versus 1.58 [HR, 3.29; 95% CI, 2.06–5.25]) and for
any stroke (6.58 versus 1.84 [HR, 2.95; 95% CI, 1.89–
4.59]), but not significantly different for hemorrhagic
Table 1. Baseline Demographic and Clinical Characteristics of the TRACER Trial Patients With and Without at Least 1 Episode of
Stroke During the Trial
Variable No Stroke (N=12 745) At Least 1 Stroke (N=199) Total (N=12 944)
Patient characteristics
Age, y 64 (58–71) 69 (60–74) 64 (58–72)
Female sex 3576 (28.1) 56 (28.1) 3632 (28.1)
Race
White 10 873 (85.5) 166 (83.8) 11 039 (85.5)
Black or African American 305 (2.4) 7 (3.5) 312 (2.4)
Asian 1042 (8.2) 14 (7.1) 1056 (8.2)
Native Hawaiian or other Pacific Islander 32 (0.3) 0 (0.0) 32 (0.2)
Multiracial 425 (3.3) 10 (5.1) 435 (3.4)
Body mass index, kg/m2 28 (25–31) 27 (25–31) 28 (25–31)
Region of enrollment
North America 3339 (26.2) 65 (32.7) 3404 (26.3)
Latin America 824 (6.5) 24 (12.1) 848 (6.6)
Europe 1 5758 (45.2) 81 (40.7) 5839 (45.1)
Europe 2 1471 (11.5) 16 (8.0) 1487 (11.5)
Asia/Pacific 925 (7.3) 11 (5.5) 936 (7.2)
Australia/New Zealand 428 (3.4) 2 (1.0) 430 (3.3)
Cardiovascular risk factors
Hypertension 8967 (70.4) 161 (80.9) 9128 (70.5)
Hypercholesterolemia 7941 (62.3) 121 (60.8) 8062 (62.3)
Diabetes mellitus 3992 (31.3) 78 (39.2) 4070 (31.5)
Smoker at enrollment 3491 (27.4) 45 (22.6) 3536 (27.3)
Comorbidities
Stroke 531 (4.2) 22 (11.1) 553 (4.3)
History of TIA 308 (2.4) 17 (8.5) 325 (2.5)
Myocardial infarction 3728 (29.3) 63 (31.7) 3791 (29.3)
Peripheral arterial vascular disease 911 (7.2) 25 (12.6) 936 (7.2)
History of atrial fibrillation 548 (4.3) 20 (10.1) 568 (4.4)
Status at time of presentation
Killip class ≤2 at enrollment 12 513 (99.0) 189 (95.5) 12 702 (99.0)
Creatinine clearance, mL/min 95 (73–122) 82 (64–103) 95 (73–121)
ECG findings
ST-segment elevation at enrollment 725 (5.7) 11 (5.5) 736 (5.7)
ST-segment depression at enrollment 4129 (32.4) 70 (35.2) 4199 (32.4)
Data presented as median (quartile 1–quartile 3) for continuous variables and as number (percentage) for discrete variables. TIA indicates transient ischemic attack; TRACER, Thrombin
Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome.
DOI: 10.1161/JAHA.118.009609 Journal of the American Heart Association 4
Strokes With Vorapaxar vs Placebo in TRACER Ungar et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 25, 2019
stroke (0.66 versus 0.27 [HR, 1.73; 95% CI, 0.41–
7.25]).
Events After Stroke
Events after first strokes are displayed in Figure S1 (A and B).
The figure subgroups patients on the basis of whether they
were assigned vorapaxar or placebo and by what type of
stroke they had: any (hemorrhagic plus nonhemorrhagic),
hemorrhagic, and nonhemorrhagic. Patients were further
subdivided on the basis of whether study drug was continued
or discontinued after their stroke, to illustrate the impact of
different management strategies on outcomes. The number of
events after stroke was small and relatively comparable
across all groups.
Discussion
Stroke occurred in <2% of patients with ACS during long-term
follow-up in the TRACER trial. Patients assigned to vorapaxar
had more hemorrhagic strokes and fewer nonhemorrhagic
strokes. Overall stroke frequency was similar between
vorapaxar- and placebo-assigned patients. Patients with a
history of stroke were 6 to 10 times more likely to have an
ischemic stroke than a hemorrhagic stroke. A small number of
adverse events occurred after stroke across all groups.
After the TRACER6 and TRA2P-TIMI 507 trials demon-
strated an increased rate of hemorrhagic stroke in vorapaxar-
treated patients, the need to better characterize vorapaxar’s
Table 2. Stroke Characteristics, Among Patients With at
Least 1 CEC-Adjudicated Stroke, by Treatment Group and
Overall
Variable
Vorapaxar
(N=96)
Placebo
(N=103)
Total
(N=199)
No. of stroke events
1 92 (95.8) 93 (90.3) 185 (93.0)
2 4 (4.2) 7 (6.8) 11 (5.5)
3 0 (0.0) 3 (2.9) 3 (1.5)
First event: type of stroke
Nonhemorrhagic
Suspected embolic 38 (39.6) 54 (52.4) 92 (46.2)
Other 36 (37.5) 39 (37.9) 75 (37.7)
With hemorrhagic conversion 3 (3.1) 4 (3.9) 7 (3.5)
Primary intracerebral
hemorrhage
15 (15.6) 3 (2.9) 18 (9.0)
Subarachnoid hemorrhage 3 (3.1) 0 (0.0) 3 (1.5)
Uncertain 1 (1.0) 3 (2.9) 4 (2.0)
Any nonhemorrhagic stroke 74 (77.1) 93 (90.3) 167 (83.9)
Any hemorrhagic stroke 22 (22.9) 8 (7.8) 30 (15.1)
Any hemorrhagic conversion 3 (3.1) 5 (4.9) 8 (4.0)
Any intracerebral hemorrhage 16 (16.7) 3 (2.9) 19 (9.5)
Any subarachnoid hemorrhage 3 (3.1) 0 (0.0) 3 (1.5)
Any stroke of uncertain type 1 (1.0) 3 (2.9) 4 (2.0)
Data are presented as number (percentage) for discrete variables. CEC indicates central
clinical events committee.
Figure. Kaplan-Meier percentage rate to 2 years in vorapaxar
vs placebo in any stroke (A), hemorrhagic stroke (B), and
nonhemorrhagic stroke (C). CI indicates confidence interval;
HR, hazard ratio.
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stroke and bleeding risk has been emphasized. Our results
build on previous studies of stroke outcomes with vorapaxar.
Earlier analyses from the TRA2P-TIMI 50 trial demonstrated
that vorapaxar-assigned patients with a history of ischemic
stroke have a higher rate of bleeding and ICH without a lower
rate of ischemic events8 and that vorapaxar-assigned patients
without a history of stroke have higher rates of hemorrhagic
stroke but lower rates of ischemic stroke and of stroke
overall.9 The TARDIS (Triple Antiplatelets for Reducing
Dependency after Ischemic Stroke) trial, which compared
intense triple therapy with guideline-based therapy (1 or 2
antiplatelet agents) in patients with ischemic stroke, has
similarly demonstrated increased bleeding with a triple
antiplatelet therapy strategy without an advantage in reducing
the incidence or severity of stroke.12 Our study expands on
these results by examining stroke type and outcomes in the
TRACER trial population, including all patients in the TRACER
trial regardless of prior stroke history, and reporting on
adverse events after stroke.
Although our findings are consistent with those of the
TRA2P-TIMI 50 trial substudies, there are several notable
differences. Although both our and prior studies demonstrate a
significantly higher rate of hemorrhagic stroke among vora-
paxar-assigned patients, we found a nonsignificantly lower rate
of ischemic stroke and a similar rate of stroke overall, whereas
the TRA2P-TIMI 50 trial substudy found a significantly lower
rate of both these outcomes. The higher overall stroke rate in
our study may be because of a higher-risk patient population.
Although the TRA2P-TIMI 50 trial substudy excluded patients
with a history of cerebrovascular accident or TIA, who are at
especially high risk of ICH with vorapaxar,8 we included
patients with this higher-risk history. In addition, patients in the
TRACER trial started receiving vorapaxar during ACS presen-
tations as opposed to at least 2 weeks after their events, as in
the TRA2P-TIMI 50 trial. Patients with ACS are more likely to be
platelet na€ıve and, thus, may carry higher bleeding risk with
initiation of triple antiplatelet therapy. Despite studying
patients who were at higher risk, we still found a similar
overall stroke rate with vorapaxar versus placebo.
Our data on stroke severity also resemble and expand on
data from the TRA2P-TIMI 50 trial. The TRA2P-TIMI 50 trial
substudy also found that the rate of hemorrhagic conversion
of nonhemorrhagic stroke was not higher among vorapaxar-
treated patients.9 We build on these results by reporting on
other adverse events after stroke, stratifying whether vora-
paxar was continued or discontinued, and assessing whether
the initial stroke was hemorrhagic or nonhemorrhagic. Our
finding of no large numerical differences in adverse events
after stroke may suggest that strokes among vorapaxar-
treated patients are of similar clinical significance. Alterna-
tively, the apparent similarities could be because of the small
number of strokes and small number of adverse events.
Table 3. Baseline Demographic and Clinical Characteristics
of the TRACER Trial Patients With Hemorrhagic Versus
Nonhemorrhagic Stroke Overall
Variable
Patients With
Hemorrhagic
Stroke (N=28)
Patients With
Nonhemorrhagic
Stroke (N=167)
Patient characteristics
Age, y 70 (62–76) 68 (60–73)
Female sex 11 (39.3) 42 (25.1)
Race
White 24 (85.7) 138 (83.1)
Black or African American 0 (0.0) 7 (4.2)
Asian 1 (3.6) 13 (7.8)
Native Hawaiian or other
Pacific Islander
0 (0.0) 0 (0.0)
Multiracial 3 (10.7) 7 (4.2)
Body mass index, kg/m2 29 (25–31) 27 (25–32)*
Region of enrollment
North America 6 (21.4) 58 (34.7)
Latin America 4 (14.3) 20 (12.0)
Europe 1 14 (50.0) 65 (38.9)
Europe 2 3 (10.7) 12 (7.2)
Asia/Pacific 1 (3.6) 10 (6.0)
Australia/New Zealand 0 (0.0) 2 (1.2)
Cardiovascular risk factors
Hypertension 19 (67.9) 138 (82.6)
Hypercholesterolemia 14 (50.0) 104 (62.3)
Diabetes mellitus 11 (39.3) 65 (38.9)
Smoker at enrollment 3 (10.7) 41 (24.6)
Comorbidities
Stroke 1 (3.6) 21 (12.6)
History of TIA 3 (10.7) 14 (8.4)
Myocardial infarction 9 (32.1) 54 (32.3)
Peripheral arterial vascular
disease
2 (7.1) 22 (13.2)
History of atrial fibrillation 2 (7.1) 17 (10.2)
Status at time of presentation
Killip class ≤2 at enrollment 27 (96.4) 158 (95.2)
Creatinine clearance, mL/min† 82 (60–102) 82 (65–105)
ECG findings
ST-segment
elevation at enrollment
1 (3.6) 10 (6.0)
ST-segment
depression at enrollment
11 (39.3) 57 (34.1)
Data are presented as median (quartile 1–quartile 3) for continuous variables and number
(percentage) for discrete variables. TIA indicates transient ischemic attack; TRACER,
Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome.
*For body mass index, N=165 for patients with nonhemorrhagic stroke.
†For creatinine clearance, N=27 for patients with hemorrhagic stroke and N=154 for
patients with nonhemorrhagic stroke.
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Larger studies with more stroke outcomes and longer
longitudinal follow-up would be required to differentiate
between these possibilities.
These results address a key question about vorapaxar on
its risk-benefit profile with regard to stroke. Although
vorapaxar was shown in the TRACER6 and TRA2P-TIMI 507
Table 4. Baseline Demographic and Clinical Characteristics of the TRACER Trial Patients With Hemorrhagic Versus
Nonhemorrhagic Stroke by Treatment Assignment
Variable
Patients With Hemorrhagic Stroke Patients With Nonhemorrhagic Stroke
Vorapaxar (N=21) Placebo (N=7) Vorapaxar (N=74) Placebo (N=93)
Patient characteristics
Age, y 69 (61–75) 74 (64–77) 66 (60–73) 69 (61–74)
Female sex 9 (42.9) 2 (28.6) 20 (27.0) 22 (23.7)
Race
White 17 (81.0) 7 (100.0) 58 (78.4) 80 (87.0)
Black or African American 0 (0.0) 0 (0.0) 1 (1.4) 6 (6.5)
Asian 1 (4.8) 0 (0.0) 8 (10.8) 5 (5.4)
Native Hawaiian or other Pacific Islander 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Multiracial 3 (14.3) 0 (0.0) 6 (8.1) 1 (1.1)
Body mass index, kg/m2* 30 (25–31) 27 (25–31) 28 (24–31) 27 (25–32)
Region of enrollment
North America 4 (19.0) 2 (28.6) 23 (31.1) 35 (37.6)
Latin America 4 (19.0) 0 (0.0) 12 (16.2) 8 (8.6)
Europe 1 11 (52.4) 3 (42.9) 26 (35.1) 39 (41.9)
Europe 2 1 (4.8) 2 (28.6) 6 (8.1) 6 (6.5)
Asia/Pacific 1 (4.8) 0 (0.0) 7 (9.5) 3 (3.2)
Australia/New Zealand 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.2)
Cardiovascular risk factors
Hypertension 13 (61.9) 6 (85.7) 60 (81.1) 78 (83.9)
Hypercholesterolemia 11 (52.4) 3 (42.9) 46 (62.2) 58 (62.4)
Diabetes mellitus 10 (47.6) 1 (14.3) 31 (41.9) 34 (36.6)
Smoker at enrollment 3 (14.3) 0 (0.0) 17 (23.0) 24 (25.8)
Comorbidities
Stroke 0 (0.0) 1 (14.3) 8 (10.8) 13 (14.0)
History of TIA 2 (9.5) 1 (14.3) 9 (12.2) 5 (5.4)
Myocardial infarction 7 (33.3) 2 (28.6) 20 (27.0) 34 (36.6)
Peripheral arterial vascular disease 1 (4.8) 1 (14.3) 6 (8.1) 16 (17.2)
History of atrial fibrillation 1 (4.8) 1 (14.3) 9 (12.2) 8 (8.6)
Status at time of presentation
Killip class ≤2 at enrollment 20 (95.2) 7 (100.0) 68 (91.9) 90 (97.8)
Creatinine clearance, mL/min† 75 (47–108) 86 (82–89) 78 (65–100) 90 (65–106)
ECG findings
ST-segment elevation at enrollment 1 (4.8) 0 (0.0) 3 (4.1) 7 (7.5)
ST-segment depression at enrollment 9 (42.9) 2 (28.6) 26 (35.1) 31 (33.3)
Data are presented as median (quartile 1–quartile 3) for continuous variables and number (percentage) for discrete variables. TIA indicates transient ischemic attack; TRACER, Thrombin
Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome.
*For body mass index for patients with nonhemorrhagic stroke, N=73 for the vorapaxar group and N=92 for the placebo group.
†For creatinine clearance for patients with hemorrhagic stroke, N=20 for the vorapaxar group; for patients with nonhemorrhagic stroke, N=69 for the vorapaxar group and N=85 for the
placebo group.
DOI: 10.1161/JAHA.118.009609 Journal of the American Heart Association 7
Strokes With Vorapaxar vs Placebo in TRACER Ungar et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 25, 2019
trials to reduce rates of cardiovascular events, concern arising
from vorapaxar’s association with ICH has resulted in limited
vorapaxar use. To evaluate the risk-benefit of vorapaxar with
regard to stroke, however, it is important not only to consider
vorapaxar’s association with hemorrhagic stroke, but also its
effect on nonhemorrhagic stroke and stroke overall. The prior
TRA2P-TIMI 50 trial data8,9 have suggested and our data seem
to confirm that although vorapaxar is associated with higher
rates of hemorrhagic stroke, it may also be associated with
similar stroke rates overall. These results should not be
overinterpreted, but it is reasonable to consider whether this
observation of similar overall stroke rates should mitigate
initial concern relating to vorapaxar’s ICH association and
whether it may shift vorapaxar’s overall risk-benefit profile
toward benefit.
Further research is needed to identify factors associated
with hemorrhagic stroke and other bleeding events with
vorapaxar. A recent meta-analysis of patients with ACS
enrolled in clinical trials identified older age, prior TIA or
cerebrovascular accident, higher systolic blood pressure, and
more antithrombotic agents as risk factors for ICH.13 We also
found an association between higher systolic blood pressure
and hemorrhagic stroke, as well as nonhemorrhagic and all
types of stroke. A next step could be developing a clinical
predictor similar to those that exist to help risk stratify
patients in other settings (eg, HAS-BLED14 and CHA2DS2-
VASc15 for anticoagulation in atrial fibrillation, the DAPT
Score16 for dual antiplatelet therapy after percutaneous
coronary intervention, and the Intracranial-B2LEED3S Score17
for risk of ICH with other antiplatelets). Another goal could be
identifying novel bleeding risk factors, including genetic and
other biomarkers. These could potentially include neuroimag-
ing biomarkers that may be associated with increased risk of
hemorrhagic stroke. In addition, clinical studies should be
performed that examine alternative antiplatelet combinations.
In the TRACER trial, vorapaxar was combined with standard
therapy per the treating physician’s discretion, which in >90%
of patients included aspirin and a P2Y12 agent, such as
clopidogrel, resulting in triple antiplatelet therapy.6 Other
schemes, such as combinations of vorapaxar with either
aspirin or a P2Y12 agent, may have less bleeding risk and
similar or more benefit. In addition, the role of vorapaxar as
monotherapy for secondary stroke prevention has not been
assessed, and future trials could compare it with current
standard of care (eg, aspirin monotherapy or aspirin plus a
P2Y12 agent) for this indication.
Limitations
This study has some limitations. First, the overall number of
strokes in the TRACER trial was small, limiting sample size
and statistical power. Second, Rankin scores (a validated
stroke severity rating scale) were not rigorously collected on
all subjects. The lack of these data limits this study’s ability to
assess the clinical significance of the strokes that occurred.
Finally, the study’s generalizability should be interpreted in
the context of differences between the study population and
the FDA-approved patient population. In this study population,
vorapaxar was started during ACS, as opposed to after a
minimum of 2 weeks after an ischemic event, as is mandated
by the FDA. This analysis also included patients with a history
of stroke or TIA, and the FDA strongly recommends against
starting vorapaxar in patients with this history.
Conclusion
We found that although vorapaxar was associated with an
increased rate of hemorrhagic stroke, it was also associated
with a nonsignificant trend toward lower ischemic stroke and
a similar rate of stroke overall. There were few adverse
events after strokes in both treatment groups. These results
contribute to our understanding of stroke types and
outcomes in vorapaxar-treated patients. Further research is
needed to identify factors associated with stroke with
vorapaxar, which could include both clinical predictors and
novel biomarkers.
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Figure S1. Events by management of vorapaxar and placebo after first stroke. 
 
A. Overall (=any stroke) 
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B. By stroke type 
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